Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs

Chinese Journal of Cancer

Volumn 33, Issue 5, 2014, Pages 223-230

  Kathawala, Rishil J ^a   Wang, Yi Jun ^a   Ashby Jr , Charles R ^a   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

ABCC10; Antitumor drugs; Multidrug resistance; Phosphodiesterase type 5 inhibitors; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; CEPHARANTHINE; CYCLOSPORIN A; CYTARABINE; DOCETAXEL; EPOTHILONE B; ERLOTINIB; GEMCITABINE; IMATINIB; LAPATINIB; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 7; NAVELBINE; NEVIRAPINE; NILOTINIB; PACLITAXEL; SILDENAFIL; SORAFENIB; TAMOXIFEN; TANDUTINIB; TARIQUIDAR; TAXANE DERIVATIVE; TENOFOVIR; VARDENAFIL; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ABCC10 PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; BENZYLISOQUINOLINE DERIVATIVE; IMIDAZOLE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SULFONAMIDE; SULFONE; TAXOID; TRIAZINE DERIVATIVE;

DRUG TRANSPORT; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; IMMUNOFLUORESCENCE; MUTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; MULTIDRUG RESISTANCE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; BENZYLISOQUINOLINES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PIPERAZINES; PURINES; PYRIMIDINES; QUINAZOLINES; SULFONAMIDES; SULFONES; TAXOIDS; TRIAZINES;

EID: 84899827544     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.013.10122     Document Type: Review

References (61)

1. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrugresistance in cancer. Nat Rev Drug Discov, 2006,5:219-234.
2. Dean M, Allikmets R. Complete characterization of the human abcgene family. J Bioenerg Biomembr, 2001,33:475-479.
3. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer:role of ATP-dependent transporters. Nat Rev Cancer, 2002,2:48-58.
4. Borst P, Evers R, Kool M, et al. A family of drug transporters: themultidrug resistance-associated proteins. J Natl Cancer Inst, 2000,92:1295-1302.
5. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistanceby ATP-binding cassette transporter genes. Biochem Biophys Acta,2007,1775:237-262.
6. Tiwari AK, Sodani K, Dai CL, et al. Revisiting the ABCs of multidrugresistance in cancer chemotherapy. Curr Pharm Biotechnol, 2011,12:570-594.
7. Sodani K, Patel A, Kathawala RJ, et al. Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer, 2012, 31:58-72.
8. Kruh GD, Guo Y, Hopper-Borge E, et al. ABCC10, ABCC11, and ABCC12. Pflugers Arch, 2007,453:675-684.
9. Hopper E, Belinsky MG, Zeng H, et al. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett, 2001,162:181-191.
10. Hopper-Borge E, Chen ZS, Shchaveleva I, et al. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res, 2004,64:4927-4930.
11. Malofeeva EV, Domanitskaya N, Gudima M, et al. Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res, 2012,72:6457-6467.
12. Chen ZS, Hopper-Borge E, Belinsky MG, et al. Characterization ofthe transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol, 2003,63:351-358.
13. Hopper-Borge EA, Churchill T, Paulose C, et al. Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice. Cancer Res, 2011,71:3649-3657.
14. Takayanagi S, Kataoka T, Ohara O, et al. Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent upregulation. J Exp Ther Oncol, 2004,4:239-246.
15. Bleasby K, Castle JC, Roberts CJ, et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica, 2006,36:963-988.
16. Kao HH, Chang MS, Cheng JF, et al. Genomic structure, gene expression, and promoter analysis of human multidrug resistance-associated protein 7. J Biomed Sci, 2003,10:98-110.
17. Bessho Y, Oguri T, Ozasa H, et al. ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. Oncol Rep, 2009,21:263-268.
18. Oguri T, Ozasa H, Uemura T, et al. MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther, 2008,7:1150-1155.
19. Hu S, Niu H, Inaba H, et al. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst, 2011,103:893-905.
20. Dabrowska M, Sirotnak FM. Regulation of transcription of the human MRP7 gene. Characteristics of the basal promoter and identification of tumor-derived transcripts encoding additional 5' end heterogeneity. Gene, 2004,341:129-139.
21. Naramoto H, Uematsu T, Uchihashi T, et al. Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines. Int J Oncol, 2007,30:393-401.
22. Hopper-Borge E, Xu X, Shen T, et al. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res, 2009,69:178-184.
23. De Souza R, Zahedi P, Badame RM, et al. Chemotherapy dosing schedule influences drug resistance development in ovarian cancer. Mol Cancer Ther, 2011,10:1289-1299.
24. Zhou Y, Hopper-Borge E, Shen T, et al. Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochem Pharmacol, 2009,77:993-1001.
25. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2002,2:117-125.
26. Gora-Tybor J, Robak T. Targeted drugs in chronic myeloid leukemia. Curr Med Chem, 2008,15:3036-3051.
27. Tiwari AK, Sodani K, Wang SR, et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol, 2009,78:153-161.
28. Shen T, Kuang YH, Ashby CR, et al. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One, 2009,4:e7520.
29. Cameron D. Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer. Clin Adv Hematol Oncol, 2007,5:456-458.
30. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol, 2007,25:1545-1552.
31. Dai CL, Tiwari AK, Wu CP, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res, 2008,68:7905-7914.
32. Shi Z, Peng XX, Kim IW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res, 2007,67:11012-11020.
33. Kuang YH, Shen T, Chen X, et al. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol, 2010,79:154-161.
34. Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist, 2004,9 Suppl 3:10-15.
35. Fabian MA, Biggs WH, 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol, 2005,23:329-336.
36. Mori S, Cortes J, Kantarjian H, et al. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma, 2008,49:2246-2255.
37. Hu S, Chen Z, Franke R, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res, 2009,15:6062-6069.
38. Corbin JD, Francis SH. Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction. J Androl, 2003,24:S38-41.
39. Shi Z, Tiwari AK, Shukla S, et al. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res, 2011,71:3029-3041.
40. Ding PR, Tiwari AK, Ohnuma S, et al. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1-P-glycoprotein transporter. PLoS One, 2011,6:e19329.
41. Chen JJ, Sun YL, Tiwari AK, et al. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding cassette C10) transporter. Cancer Sci, 2012,103:1531-1537.
42. Klinkhammer W, Muller H, Globisch C, et al. Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators. Bioorg Med Chem, 2009,17:2524-2535.
43. Smith AJ, Mayer U, Schinkel AH, et al. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J Natl Cancer Inst, 1998,90:1161-1166.
44. Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res, 2001,61:749-758.
45. Kuhnle M, Egger M, Muller C, et al. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem, 2009,52:1190-1197.
46. Illmer T, Ehninger G. FLT3 kinase inhibitors in the management of acute myeloid leukemia. Clin Lymphoma Myeloma, 2007,8 Suppl 1:S24-34.
47. Deng W, Dai CL, Chen JJ, et al. Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10). Oncol Rep, 2013,29:2479-2485.
48. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis, 2011,204:145-153.
49. ElSharawy A, Hundrieser B, Brosch M, et al. Systematic evaluation of the effect of common SNPs on pre-mRNA splicing. Hum Mutat, 2009,30:625-632.
50. Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol, 2009,5:563-573.
51. Gatanaga H, Tachikawa N, Kikuchi Y, et al. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses, 2006,22:744-748.
52. Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS, 2004,18:1074-1076.
53. Earle KE, Seneviratne T, Shaker J, et al. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res, 2004,19:714-721.
54. Liptrott NJ, Pushpakom S, Wyen C, et al. Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDs. Pharmacogenet Genomics, 2012,22:10-19.
55. de Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet, 2003,42:599-605.
56. Duong M, Buisson M, Peytavin G, et al. Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors. Ann Pharmacother, 2005,39:603-609.
57. Kao HH, Huang JD, Chang MS. cDNA cloning and genomic organization of the murine MRP7, a new ATP-binding cassette transporter. Gene, 2002,286:299-306.
58. Wooden SL, Kalb SR, Cotter RJ, et al. Cutting edge: HLA-E binds a peptide derived from the ATP-binding cassette transporter multidrug resistance-associated protein 7 and inhibits NK cellmediated lysis. J Immunol, 2005,175:1383-1387.
59. Zahedi P, De Souza R, Huynh L, et al. Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer. Mol Pharm, 2011,8:260-269.
60. Tiwari AK, Sodani K, Dai CL, et al. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett, 2013,328:307-317.
61. Sun YL, Chen JJ, Kumar P, et al. Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. PLoS One, 2013, 8:e55576.